Multiple sclerosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 9,555 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices

  NCT07066137· IRCCS Centro Neurolesi Bonino Pulejo· Source

• Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

  NCT07376772· University of Florida· Source

• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Zenas BioPharma (USA), LLC· Source

• Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

  NCT04480853· Novartis Pharmaceuticals· Source

• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

  NCT07609719· Genentech, Inc.· Source

• Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity

  2024-517745-14-00· Celgene Corp.· Source

• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Hoffmann-La Roche· Source

• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Sanofi-Aventis Recherche & Developpement· Source

• An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

  NCT06675955· Hoffmann-La Roche· Source

• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Zenas BioPharma (USA), LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 16
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 3
• Gene Expression Profiling 38
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 34
• Metabolomics 21
• Mass Spectrometry 12
• Flow Cytometry 29
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 559
• Machine Learning 43
• Deep Learning 32
• Cohort Studies 181
• Genome-Wide Association Study 84

• A candidate CD4⁺ T-cell gene expression panel for multiple sclerosis highlights MgADP-associated genes.

  Mult Scler Relat Disord, Sept 2026

• Machine learning identifies microbiome and clinical predictors of sustained weight loss following prolonged fasting.

  Genome Med, Sept 2026

• Machine Learning for Noninvasive Diagnosis of Neurodegenerative Diseases Using Retinal and Optic Nerve Imaging: A Comprehensive Review.

  Annu Rev Vis Sci, Sept 2026

• Multimodal MRI biomarkers and machine learning in neuromyelitis optica spectrum disorder: a review.

  Front Neurol, Aug 2026

• Machine Learning-Based Prediction of Sleep Quality in Patients with Multiple Sclerosis.

  Med Sci (Basel), Aug 2026

• Artificial intelligence-based monitoring of multiple sclerosis: A comprehensive survey.

  Mult Scler Relat Disord, Aug 2026

• Manual federated simulation for multiple sclerosis integrating XGBoost algorithm with SHAP explanation.

  Sci Rep, Jul 2026

• A multi-outcome prognostic score for therapeutic responses in multiple sclerosis.

  Rev Neurol (Paris), Jul 2026

• Microstructural changes in juxtacortical white matter regions and their relationship with PASAT score in multiple sclerosis: A proof of concept using machine learning.

  Mult Scler Relat Disord, Jun 2026

• Exploratory analysis of pupillography-based machine learning for assessing autonomic dysfunction in multiple sclerosis.

  Mult Scler Relat Disord, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.